Development of Novel Inhibitors of New Delhi Metallo-beta-lactamase-1 (NDM-1)
This invention represents a major discovery because there are currently no approved drugs to block NDM-1. These discoveries could lead to development of new therapeutics to treat these highly pathogenic and resistant bacteria.
The new inhibitors for NDM-1 are targeted toward the very pathogenic multidrug-resistant bacteria such as carbapenem-resistant Enterobacteriacae and Klebsiella pneumoniae.
Researchers at UC San Diego have successfully designed and synthesized a new class of inhibitors for New Delhi Metallo-betalactamase-1 (NDM-1) and two related beta-lactamases. They exhibit remarkable selectivity as they don’t hit other Zn(II) metalloenzymes. The inhibitors restored susceptibility to imipenem in three different E.coli strains, including a clinical isolate expressing blaNDM-1.
State Of Development The inventors have used a fragment-based drug discovery platform to identify a new class of inhibitors for NDM-1 and two related B-lactamases. The inhibitors were found to be highly selective for metallo-β-lactamases when compared to other Zn(II) metalloenzymes. Intellectual Property Info A provisional patent has been submitted and the technology is available to license. Related Materials Tech ID/UC Case 29251/2017-259-0 Related Cases 2017-259-0
美國
